MAPT and Alzheimer disease: Alzheimer’s disease (AD) is a progressiveneurodegenerativedisorder and the leading cause of dementia, currently affecting morethan six million individuals globally. Although characterized by the accumulation of β-amyloid (Aβ)plaques and hyperphosphorylated tau tangles, therapeutic strategiestargeting Aβ clearance have yielded limited clinical benefitdespite substantial plaque reduction.−,  These findings underscorethe urgent need to explore alternative, druggable mechanisms.